Veru Inc.
VERU
Rank in Stocks
#23918
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing... Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
Share Price
$2.19
Last synced: 2026-11-09
Market Cap
$37.34M
Change (1 day)
3.30%
Change (1 year)
-19.78%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Veru Inc. (VERU)
Category
Healthcare
EPS for Veru Inc. (VERU)
EPS as of June 2026 TTM: $-0.60
According to Veru Inc.'s latest financial reports, its current EPS (TTM) is $-0.60. At the end of 2025 the company had an EPS of $-1.55, an increase over its 2024 EPS of $-2.80.
EPS history for Veru Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.60 | -61.29% |
| 2025 | $-1.55 | -44.64% |
| 2024 | $-2.80 | -74.45% |
| 2023 | $-10.96 | 4.48% |
| 2022 | $-10.49 | -1,149.00% |
| 2021 | $1.00 | -135.21% |
| 2020 | $-2.84 | 49.47% |
| 2019 | $-1.90 | -57.25% |
| 2018 | $-4.44 | 78.96% |
| 2017 | $-2.48 | -2,583.50% |
| 2016 | $0.10 | -93.33% |
| 2015 | $1.50 | 66.67% |
| 2014 | $0.90 | -82.35% |
| 2013 | $5.10 | -7.27% |
| 2012 | $5.50 | 175.00% |
| 2011 | $2.00 | -20.00% |
| 2010 | $2.50 | 0.00% |
| 2009 | $2.50 | 38.89% |
| 2008 | $1.80 | 200.00% |
| 2007 | $0.60 | 500.00% |
| 2006 | $0.10 | -114.29% |
| 2005 | $-0.70 | 536.36% |
| 2004 | $-0.11 | -8.33% |
| 2003 | $-0.12 | -42.86% |
| 2002 | $-0.21 | 162.17% |
| 2001 | $-0.08 | -72.38% |
| 2000 | $-0.29 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -2,710.00% |
US
|
|
| $-7.07 | 1,078.33% |
US
|
|
| $-5.29 | 781.67% |
AU
|
|
| $12.88 | -2,246.68% |
BE
|
|
| $21.56 | -3,693.33% |
NL
|
Questions about Veru Inc.'s earnings per share (EPS)
What is Veru Inc.'s earnings per share (EPS)?
Veru Inc.'s earnings per share (EPS) over the last twelve months is $-0.60, as of Jun 2026.
What was Veru Inc.'s earnings per share (EPS) in 2025?
In 2025, Veru Inc.'s earnings per share (EPS) was $-1.55, compared with $-2.80 in 2024.
How has Veru Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Veru Inc.'s earnings per share (EPS) was highest in 2021 ($1.00) and lowest in 2023 ($-10.96).
How does Veru Inc.'s earnings per share (EPS) compare with similar companies?
Veru Inc.'s earnings per share (EPS) ($-0.60) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.